Search

Your search keyword '"Sham, Jonathan S. T."' showing total 35 results
Start Over Author "Sham, Jonathan S. T." Publisher wiley-blackwell
35 results on '"Sham, Jonathan S. T."'

2. Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma.

Author

Chua, Daniel T. T., Wei, William I., Wong, Maria P., Sham, Jonathan S. T., Nicholls, John, and Au, Gordon K. H.

Subjects
MEDICAL research, NASOPHARYNX cancer, EPITHELIAL cells, CANCER treatment, DRUG therapy, THERAPEUTICS
Abstract

Background This single-center, phase II study assessed the safety/tolerability and initial efficacy of gefitinib in patients with nasopharyngeal carcinoma (NPC) pretreated with platinum-based chemotherapy. Methods Patients with recurrent and metastatic NPC who had treatment failure with at least 2 lines of chemotherapy including platinum were given gefitinib at a fixed dose of 250 mg daily. Treatment was continued until the patient experienced unacceptable side effects or disease progression. Results Nineteen patients were enrolled, having had treatment failure with a median of 2 chemotherapy regimens. Treatment was well tolerated, and only grades 1 to 2 adverse events were observed. None of the patients achieved partial or complete response. Median time-to-progression was 4 months, and median overall survival was 16 months. Conclusion Gefitinib was well tolerated, but the response rate was poor in this heavily pretreated study population, and its use in NPC is not recommended outside the context of clinical trial. © 2008 Wiley Periodicals, Inc. Head Neck, 2008 [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

3. Complementary activation of peripheral natural killer cell immunity in nasopharyngeal carcinoma.

Author

Ying Zheng, Kai-Yuan Cao, Sze Park Ng, Chua, Daniel T. T., Sham, Jonathan S. T., Kwong, Dora L. W., Mun Hon Ng, Liwei Lu, and Bo-Jian Zheng

Subjects
KILLER cells, CELLULAR immunity, TUMORS, MYELOMA proteins, CELL-mediated cytotoxicity
Abstract

NK cells and αβ- and γδ-CTL play important roles in cellular immunity against tumors. We previously demonstrated that NPC patients have a quantitative and qualitative deficit in γδ-CTL and EBV-specific αβ-CTL when compared to normal subjects and NPC long-term survivors. In this study we report further observations of a complementary activation of peripheral NK cells in NPC patients. The NK cells in these patients, compared to those of healthy subjects and NPC survivors, were preferentially activated in response to the stimulation of myeloma cell line XG-7 and expanded in the presence of exogenous IL-2. The production of IFN-γ was lowest in the patient group, whereas IL-12, IL-15 and TNF-α were produced in higher levels in patients than in the donors and survivors. The cytolytic effect of the NK cells against NPC cells in the patient group was also higher than that of the donors and survivors. Furthermore, the patients at later stages of NPC had lower γδ-CTL activity but higher NK cytotoxicity towards NPC targets, with higher production of IL-12, IL-15 and TNF-α but lower production of IFN-γ than in patients at earlier stages. This might be part of a triggered compensatory re-activation of the innate immunity, believed to be mediated through various cytokines and chemokines when adaptive T cell immunity is breached. Together, these data suggest complementary roles of innate and adaptive immune response in tumor immunity where NK cells, γδ- and αβ-CTL compensate for the deficits of one another at different stages of tumor invasion. ( Cancer Sci 2006; 97: 912–919) [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

4. Preservation of quality of life after intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: Results of a prospective longitudinal study.

Author

McMillan, Anne S., Pow, Edmond H. N., Kwong, Dora L. W., Wong, May C. M., Sham, Jonathan S. T., Leung, Lucullus H. T., and Leung, W. Keung

Subjects
RADIOTHERAPY, QUALITY of life, HEALTH status indicators, CANCER radiotherapy complications, PHARYNGEAL cancer, CANCER treatment
Abstract

Background. Xerostomia is a ubiquitous complication after conventional radiotherapy for nasopharyngeal carcinoma (NPC) that seriously impairs patient quality of life (QOL). The effect on QOL of parotid-sparing intensity-modulated radiotherapy (IMRT) for early-stage NPC was assessed prospectively. Methods. Thirty-two patients with T1–2,N0–1,M0 NPC received IMRT. Saliva flow was measured, and the Medical Outcomes Short Form 36 (SF-36), European Organization for Research and Treatment of Cancer (EORTC) core, and EORTC head and neck module (QLQ-H&N35) questionnaires were completed at baseline and 2, 6, and 12 months after IMRT. Results. Saliva flow recovered to at least 25% of baseline in most cases after 1 year. Physical function, fatigue, and vitality were problems at 2 months and then resolved (p ≤ .002). Global health scales showed continuous improvement in QOL after treatment (p ≤ .004). Xerostomia and sticky saliva were problems 2 months after treatment; thereafter, continuous improvement occurred (p ≤ .001). Xerostomia scores correlated with general aspects of QOL (p ≤ .044). Conclusion. IMRT for early-stage disease preserved key aspects of QOL, and a reduction in xerostomia symptoms enhanced broader aspects of QOL. © 2006 Wiley Periodicals, Inc. Head Neck, 2006 [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

15. Preliminary report of the asian-oceanian clinical oncology association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma

Author

Chua, Daniel T. T., Sham, Jonathan S. T., Choy, Damon, Lorvidhaya, Virchan, Sumitsawan, Yupa, Thongprasert, Sumitra, Vootiprux, Visoot, Cheirsilpa, Arkom, Azhar, Tahir, and Reksodiputro, Ary H.

Published
1998
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results